Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
General Discussion
Related: Editorials & Other Articles, Issue Forums, Alliance Forums, Region ForumsMt Sinai Study: Blood Thinners May Improve Survival Among Hospitalized COVID-19 Patients
Cath Lab Digest
May 6, 2020
Research could change standard-of-care protocols to prevent clotting associated with coronavirus
Treating hospitalized COVID-19 patients with anticoagulants may improve their chances of survival, researchers from the Mount Sinai COVID Informatics Center report. The study, published in the May 6 issue of the Journal of the American College of Cardiology, could provide new insight on how to treat and manage coronavirus patients once they are admitted to the hospital.
The study found that hospitalized COVID-19 patients treated with anticoagulants had improved outcomes both in and out of the intensive care unit setting. The research also showed that the difference in bleeding events among patients treated with and without anticoagulants was not significant. The Mount Sinai researchers say their work outlines an important therapeutic pathway for COVID-19 patients.
This research demonstrates anticoagulants taken orally, subcutaneously, or intravenously may play a major role in caring for COVID-19 patients, and these may prevent possible deadly events associated with coronavirus, including heart attack, stroke, and pulmonary embolism, says senior corresponding author Valentin Fuster, MD, PhD, Director of Mount Sinai Heart (The nations number six ranked hospital in Cardiology/Heart Surgery) and Physician-in-Chief of The Mount Sinai Hospital. Using anticoagulants should be considered when patients get admitted to the ER and have tested positive for COVID-19 to possibly improve outcomes. However, each case should be evaluated an individualized basis to account for potential bleeding risk.
The publication of this study follows recent research out of the Icahn School of Medicine at Mount Sinai that shows a large number of patients hospitalized with COVID-19 have developed high levels of life-threatening blood clots, leading to potentially deadly thromboembolic events.
Treating hospitalized COVID-19 patients with anticoagulants may improve their chances of survival, researchers from the Mount Sinai COVID Informatics Center report. The study, published in the May 6 issue of the Journal of the American College of Cardiology, could provide new insight on how to treat and manage coronavirus patients once they are admitted to the hospital.
The study found that hospitalized COVID-19 patients treated with anticoagulants had improved outcomes both in and out of the intensive care unit setting. The research also showed that the difference in bleeding events among patients treated with and without anticoagulants was not significant. The Mount Sinai researchers say their work outlines an important therapeutic pathway for COVID-19 patients.
This research demonstrates anticoagulants taken orally, subcutaneously, or intravenously may play a major role in caring for COVID-19 patients, and these may prevent possible deadly events associated with coronavirus, including heart attack, stroke, and pulmonary embolism, says senior corresponding author Valentin Fuster, MD, PhD, Director of Mount Sinai Heart (The nations number six ranked hospital in Cardiology/Heart Surgery) and Physician-in-Chief of The Mount Sinai Hospital. Using anticoagulants should be considered when patients get admitted to the ER and have tested positive for COVID-19 to possibly improve outcomes. However, each case should be evaluated an individualized basis to account for potential bleeding risk.
The publication of this study follows recent research out of the Icahn School of Medicine at Mount Sinai that shows a large number of patients hospitalized with COVID-19 have developed high levels of life-threatening blood clots, leading to potentially deadly thromboembolic events.
Read more: https://www.cathlabdigest.com/content/mt-sinai-study-blood-thinners-may-improve-survival-among-hospitalized-covid-19-patients
InfoView thread info, including edit history
TrashPut this thread in your Trash Can (My DU » Trash Can)
BookmarkAdd this thread to your Bookmarks (My DU » Bookmarks)
5 replies, 632 views
ShareGet links to this post and/or share on social media
AlertAlert this post for a rule violation
PowersThere are no powers you can use on this post
EditCannot edit other people's posts
ReplyReply to this post
EditCannot edit other people's posts
Rec (4)
ReplyReply to this post
5 replies
= new reply since forum marked as read
Highlight:
NoneDon't highlight anything
5 newestHighlight 5 most recent replies
Mt Sinai Study: Blood Thinners May Improve Survival Among Hospitalized COVID-19 Patients (Original Post)
Mike 03
May 2020
OP
I have been taking baby aspirin every day recently after hearing about the blood clots.
Quixote1818
May 2020
#1
Quixote1818
(28,936 posts)1. I have been taking baby aspirin every day recently after hearing about the blood clots.
Figure it can't hurt and might really help if I get it and haven't developed symptoms.
doc03
(35,337 posts)2. I have a head start I already take them. nt
Hermit-The-Prog
(33,345 posts)4. And I just stopped a month ago, except for 81mg aspirin.
MissMillie
(38,557 posts)5. someone please point out to the MAGAts
that the study is about blood thinners and not paint thinner.